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Abstract
Purpose Imaging with positron emission tomography
(PET) using 18F-2-fluoro-2-deoxy-D-glucose (FDG) plays
an increasingly important role for response assessment in
oncology. Several methods for quantifying FDG PET
results exist. The goal of this study was to analyse and
compare various semi-quantitative measures for response
assessment with full kinetic analysis, specifically in
assessment of novel therapies.
Methods Baseline and response dynamic FDG studies from
two different longitudinal studies (study A: seven subjects
with lung cancer and study B: six subjects with gastroin-
testinal cancer) with targeted therapies were reviewed.
Quantification of tumour uptake included full kinetic
methods, i.e. nonlinear regression (NLR) and Patlak
analyses, and simplified measures such as the simplified
kinetic method (SKM) and standardized uptake value
(SUV). An image-derived input function was used for
NLR and Patlak analysis.
Results There were 18 and 9 lesions defined for two
response monitoring studies (A and B). In all cases there
was excellent correlation between Patlak- and NLR-derived
response (R2>0.96). Percentage changes seen with SUV
were significantly different from those seen with Patlak for
both studies (p<0.05). After correcting SUV for plasma
glucose, SUV and Patlak responses became similar for
study A, but large differences remained for study B. Further
analysis revealed that differences in responses amongst
methods in study B were primarily due to changes in the
arterial input functions.
Conclusion Use of simplified methods for assessment of
drug efficacy or treatment response may provide different
results than those seen with full kinetic analysis.
Keywords FDG PET. SUV. Patlak . NLR . Response
monitoring
Introduction
Positron emission tomography (PET) using 18F-2-fluoro-2-
deoxy-D-glucose (FDG) is important for detection, staging,
prognosis and assessment of treatment response in oncol-
ogy [1–10]. Response monitoring using FDG PET has been
implemented in a variety of tumours [9, 11]. Although
criteria have been defined for evaluating PET studies using
visual inspection [12, 13], quantification of FDG uptake is
helpful for objective assessment of response to therapy.
The most common method for quantifying tumour FDG
uptake is the use of standardized uptake values (SUV).
Limitations of SUV include its dependency on patient
preparation, scanning procedure, image reconstruction and
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image analysis procedures [9, 14]. These limitations,
however, can to a large extent be overcome by proper
standardized procedures [9, 14, 15].
Apart from SUV, various other more quantitative
measures can be used for analysis of FDG PET studies.
Young et al. [16] first provided guidelines for the
measurement of tumour response to therapy using FDG
PET imaging. Quantitative approaches range from visual
assessment, through semi-quantitative methods (e.g. SUV),
to full kinetic analysis (Patlak). However, the European
Organization for Research and Treatment of Cancer
(EORTC) report did not address the accuracy or limitations
of the various analytical methods for monitoring response.
Hoekstra et al. [11, 17] compared various methods for
quantifying FDG uptake in non-small cell lung cancer
(NSCLC) such as nonlinear regression (NLR) of the data
using a pharmacokinetic model, Patlak analysis and various
simplified methods, e.g. the simplified kinetic method
(SKM) [18], SUV normalized by body surface area and
corrected for glucose (SUVBSAg) and SadatoBSA [19]. Most
measures correlated well with NLR (R2 > 0.95).
Lammertsma et al. [20] discussed the relationship between
these simplified methods and full kinetic analysis for
monitoring response to classic cytotoxic drugs. Both groups
of authors emphasized that care should be taken in using
simplified methods (i.e. SUV-based methods) for evaluation
of new drugs.
Potential discrepancies between SUV and full kinetic
analysis results may be caused by changes in plasma glucose
levels or differences in FDG plasma clearance among scans.
Factors potentially affecting the relation between SUV and
full kinetic analysis have been described by Freedman et al.
[21, 22]. Moreover, lower SUV in patients with high plasma
glucose levels has been reported [23].
Full kinetic approaches are considered most quantitative
as they use the entire (measured) arterial input and tumour
time-activity curves (TAC) in combination with a tracer
kinetic model and plasma glucose levels to derive a more
quantitative measure of the metabolic rate of glucose.
In order to correctly interpret SUV results, it has been
recommended [15, 16] that a formal comparison with full
kinetic approaches be included during early drug develop-
ment trials. Although good correlation of the percentage
change between SUV and Patlak over all tumour pairs has
been reported [11, 21], there were differences when
monitoring individual subject data [21, 24, 25]. These
authors concluded that the two measures were not equiv-
alent and that they may not equally be affected by changes
occurring during treatment. Only after SUV responses have
been validated against those seen using full quantitative
analysis could SUV be used in a larger clinical setting [14,
20, 26]. The aim of the present study was to compare
various semi-quantitative measures with full kinetic analy-
sis for assessing response to treatment. Although similar
comparisons have been performed previously, these mainly
involved classic cytotoxic drugs. In contrast, in the present
study, simplified methods were evaluated for use with novel
drugs.
Materials and methods
Subjects and study design
Data from two separate response monitoring studies, involv-
ing different drugs, were used, which will be referred to as
studies A and B. These studies were selected based on
targeted treatment. Written informed consent was obtained for
all subjects and studies were approved by the Medical Ethics
Review Committee of the VU University Medical Center.
Study A
Seven subjects suffering from stage IIIB and IV NSCLC,
enrolled in a response monitoring trial, were included in
this study. Patients were treated with an orally active
inhibitor of the epidermal growth factor receptor (EGFR)
tyrosine kinase (erlotinib). Erlotinib (Tarceva, drug A)
inhibits EGF-dependent proliferation of cells at submicro-
molar concentrations and blocks cell cycle progression in
the G1 phase, and is taken orally on a daily basis. All
patients (four women and three men; mean body weight at
baseline 74±16 kg, range 53–109 kg; mean body weight at
response scan 79±16 kg, range 60–108 kg) underwent a
dynamic FDG PET scan at baseline and after 3 weeks of
therapy.
Study B
Six patients (one woman and five men) with advanced
gastrointestinal malignancies were treated by BMS-582664
(brivanib alaninate) in combination with full-dose cetux-
imab (Erbitux), a monoclonal antibody targeting EGFR.
BMS-582664 (drug B) is a selective dual inhibitor of
fibroblast growth factor and vascular endothelial growth
factor signalling, and is taken orally on a daily schedule.
All patients (mean body weight 84±17 kg, range 60–
110 kg) underwent a dynamic baseline FDG PET scan
within 2 weeks before start of treatment. Two dynamic
response FDG PET scans were performed. Five patients
(mean body weight 84±19 kg, range 63–110 kg) underwent
an early response study during cycle 1 (day 15) of treatment
and three patients (mean body weight 88±13 kg, range 73–
108 kg) underwent a late response study after cycle 2 (day
56) of treatment. Thus, there were two subjects that
underwent both an early and a late response study.
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PET scanning protocol
All patients fasted for at least 6 h before scanning. Patients
were prepared in accordance with recently published
guidelines for quantitative FDG PET studies [14, 27].
Patients were scanned in the supine position. Patients
received an intravenous catheter for administration of
FDG and for collection of additional blood samples to
measure blood glucose (i.e. at 35, 45, 55 min post-injection
during dynamic scanning) using validated and calibrated
methods. Blood glucose levels were used for quantitative
analysis, but because of the strict study design, patients
could not be rescheduled in cases of high glucose levels. In
addition, whole blood and plasma FDG concentrations
were measured using a cross-calibrated well counter.
All studies were performed using an ECAT EXACT HR+
scanner (Siemens/CTI, Knoxville, TN, USA). The character-
istics of this scanner have been described previously [28].
Each PET study started with a 10-min transmission scan.
After completion of the transmission scan, a bolus of about
370 MBq FDG was injected intravenously and a dynamic
emission scan was started simultaneously in a two-
dimensional acquisition mode. This dynamic emission scan
consisted of 40 frames with the following lengths: 1×30, 6×
5, 6×10, 3×20, 5×30, 5×60, 8×150, 6×300 s.
All emission scans were reconstructed using filtered
backprojection (FBP) with a 0.5 Hanning filter. During
reconstruction all corrections needed for quantification,
such as dead time, decay, scatter, random, attenuation and
normalization corrections, were applied. In addition, the last
three frames of the sinogram were summed and recon-
structed using normalization and attenuation-weighted
ordered subsets expectation maximization (OSEM) with 2
iterations and 16 subsets, followed by post-smoothing using
a 0.5 Hanning filter [29]. Consequently, OSEM recon-
structed images had the same dimensions and spatial
resolution as FBP reconstructed images. OSEM reconstruc-
tions were used for volumes of interest (VOI) definition,
because of its superior image quality compared with FBP
reconstructions.
VOI definition
To obtain image-derived input functions (IDIF), 3-D VOI
were drawn manually in three vascular structures (i.e. left
ventricle, aortic arch and ascending aorta) using an early
frame highlighting the blood pool [30]. These VOI were
then projected onto all frames yielding arterial whole blood
TAC, i.e. image-derived input functions. A quality check of
each IDIF was performed, as described previously [11, 17].
This involved comparison of the three IDIFs with the
activity concentration measured in the three venous blood
samples. The maximum discrepancy allowed was 7%,
which is two times the repeatability of the blood sample
well counter measurements. Average input curves from the
three VOI defined in the three vascular structures were used
as input function during kinetic analysis. Tumour VOI were
defined on the OSEM reconstructed images using a semi-
automatic procedure [14, 27] based on a source to
background-adapted 50% isocontour. These VOI were then
projected onto all frames of the FBP reconstructed dynamic
study to provide tumour TAC. Whenever possible, TAC for
up to five lesions per patient was defined. The same lesions
were selected for all longitudinal scans of a patient.
Quantitative analysis and kinetic modelling
Four quantitative methods were investigated. These meth-
ods have been described in detail before [11] and a brief
summary is described below:
1. NLR is the most quantitative method and involves fitting
tumour TAC to the standard two-tissue irreversible
compartment model (three rate constants plus blood
volume fraction parameter) using an IDIF as arterial input
function. The primary outcome parameters of this method
are the overall influx rate constant (Ki) in min
−1 and the
metabolic rate of glucose (MRGlu) in mmol⋅l−1⋅min−1,
which equals Ki times blood glucose. The lumped
constant was assumed to be equal to 1 in all studies.
2. Patlak graphical analysis is based on a linearization of the
standard FDG model mentioned above, assuming that the
free concentration of FDG in tissue reaches a steady state
and that binding/trapping is irreversible. As the method is
rapid and robust in the presence of noise, it has been
recommended by the EORTC [16]. The primary outcome
parameters of this method again are Ki and MRGlu. In the
Patlak method, linear regression is applied to a certain
(user-defined) time interval of the collected data. Al-
though, in the present study, various time intervals were
investigated, only results for the interval 10–60 min post-
injection will be presented, as these showed the best
correlation (R2=0.97) with results obtained using NLR.
3. SKM: in contrast to NLR and Patlak, this method [18]
only requires a static FDG scan and, in principle, a
single venous blood sample obtained at 55 min post-
injection. SKM can (partly) compensate for e.g. differ-
ences in FDG clearance from blood between various
subjects or scans. SKM uses a tri-exponential function
to describe the input function. The parameters of this
function are partly based on population average value,
but the third exponential function, describing the tail, is
called using the blood concentration measured in a few
blood samples. The primary outcome parameter of
SKM is MRGlu.
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4. SUV: various SUV alternatives were investigated,
which were based on different normalization proce-
dures, e.g. body weight (SUVBW), body surface area
(SUVBSA) and lean body mass (SUVLBM). In addition,
all SUV parameters were calculated with and without a
correction for blood glucose.
SKM and SUV are based on static PET images, i.e. they
use the FDG concentration at a fixed time after FDG
administration. In the present study dynamic scans were
performed and thus the average tumour activity concentra-
tion observed at 50–60 min post-injection was used for
calculations.
Comparison of methods
Patlak analysis has been recommended by the EORTC [16]
as the method of choice for a full quantitative analysis of
dynamic FDG PET studies. To assess whether this
guideline is still valid for targeted therapies, Patlak-
derived Ki and MRGlu values were compared with those
obtained using NLR fitting of TAC using a two-tissue
compartment model with blood volume fraction correction.
Quantitative measures of FDG uptake in response scans
were related to those obtained during baseline scans and
fractional or percentage changes calculated. Percentage
changes in tracer uptake due to therapy seen with various
simplified methods and derived on a lesion per lesion basis
were correlated against those obtained using MRGlu-Patlak.
Comparison of input functions
As SUV assumes a constant relationship between injected
radioactivity and body distribution, possible discrepancies
in observed fractional changes (relative to full kinetic
analysis) may be due to therapy-induced changes in shape
and/or amplitude of the input function. Therefore, normal-
ized areas under the curve (AUC) of observed input
functions were calculated. Normalization was performed
by dividing the observed AUC of the input function by the
net amount of administered dose. Normalized AUC
(nAUC) obtained during response scans were compared
with those at baseline.
Results
For study A, 18 lesions were defined over the 7 subjects.
The mean (±SD) plasma glucose level was 6.5±3.3 (range
4.0–14.1) mmol⋅l−1 for baseline studies and 7.1±4.1 (range
4.5–16.0) mmol⋅l−1 for response studies (p=NS, Student’s t
test). Although the subjects were well prepared, high
plasma glucose levels (>8 mmol⋅l−1) were seen for two
subjects at baseline and/or after treatment. All other
subjects showed plasma glucose levels lower than
6 mmol⋅l−1.
Similarly, for study B, nine lesions from six subjects
were analysed. However, for five subjects early response
studies were available; of these five only two subjects
successfully concluded the late response studies. For one
subject only a late response study was successfully
collected. The mean plasma glucose level was 5.6±0.9
(range 3.8–7.1) mmol⋅l−1 for baseline and 5.5±1.36 (range
4.2–8.4) mmol⋅l−1 for response (p=NS, Student’s t test). All
plasma glucose levels were within normal range [6, 11].
Validation of Patlak against NLR
A comparison of Patlak- versus NLR-derived MRGlu is
given in Fig. 1 for both studies. Correlations were excellent
(all R2>0.96) for both studies, both at baseline and
following therapy (Table 1). Moreover, slopes were close
to 1 and did not significantly change between baseline and
response studies. Although good correlations were found,
there were small differences in MRGlu values between those
derived using NLR versus Patlak. These differences,
however, correlated with fitted blood volume fractions, as
shown in Fig. 2.
Correlation of methods
Results of the comparison of simplified methods against
MRGlu-Patlak are summarized in Tables 2 (study A) and 3
(study B).
In the case of study A, fair correlation (approximately R2>
0.6) was seen at baseline for all simplified methods. In
response studies, however, correlations worsened for those
methods that do not correct for plasma glucose levels, i.e.
SUVBW, SUVBSA and SUVLBM, and were significantly
better for methods that correct for plasma glucose levels.
When removing subjects with high blood glucose values
(>11 mmol⋅l−1), correlation between SUV and MRGlu-Patlak
improved considerably for most SUV measures. In the case
of study B, effects of plasma glucose corrections on
correlations were not seen. In this particular study, however,
(all) simplified methods (independent of plasma glucose
correction) provided poorer correlations for baseline studies
than for response studies.
Response assessment: comparison of methods
Study A The mean fractional change in MRGlu-Patlak
following therapy was 26±35% (range −24 to 87%), i.e.
for most subjects and lesions an increase in MRGlu was
observed, possibly indicating progression of disease.
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Clinical interpretation of these results is beyond the scope
of the present study. In Fig. 3 fractional changes obtained
using simplified methods are plotted against those seen
using MRGlu-Patlak. Percentage changes obtained using
various SUV measures without glucose correction may, at
times, differ substantially from those seen using MRGlu-
Patlak. It should be noted, however, that the largest
deviations were observed for two subjects with the highest
plasma glucose values (>8 mmol⋅l−1). Figure 3a also
illustrates that results for SUVBW, SUVBSA and SUVLBM
were very similar. Fractional changes obtained using SUV
with plasma glucose correction (Fig. 3b) and SKM (Fig. 3c)
generally showed good agreement with those obtained
using MRGlu-Patlak.
Study B The mean fractional change in MRGlu-Patlak
following therapy was −34±25% (range −64 to 34%). In
Fig. 4 fractional changes obtained using simplified methods
are plotted against those obtained using MRGlu-Patlak.
Figure 4a illustrates results obtained with various SUV
measures without glucose correction, whilst results after
glucose correction are presented in Fig. 4b. Figure 4c
shows data obtained using SKM. Note that in these figures
we illustrated results for the primary lesion only to avoid
unbalanced representation of subject data. From these
figures it can be deduced that all simplified methods
provide smaller fractional changes than MRGlu-Patlak.
Interestingly, in this case, plasma glucose correction did
not reduce the discrepancy between SUV and MRGlu-
Patlak. Similar results were obtained for SUV measures
with different normalization factors (BW, BSA, LBM).
Fractional changes found with SKM, however, seemed to
agree slightly better with those found with MRGlu-Patlak
(Fig. 4c). Tables 4 and 5 summarize all correlation
coefficients and slopes for studies A and B, respectively.
nAUC of input functions
Figure 5 illustrates the correlation of nAUC of input
functions between response and baseline studies. For study
A (Fig. 5a), nAUC of the input function were similar for
baseline and response studies. In contrast, for study B
(Fig. 5b) differences were seen for some cases.
Discussion
Validation of Patlak analysis for response assessment
For both studies very good correlations (R2>0.96) between
MRGlu-NLR and MRGlu-Patlak were found. This finding
corresponds with previously published data [11] and
supports the EORTC recommendation of using Patlak
analysis for quantification of MRGlu [16]. A possible
limitation of Patlak analysis, however, is that a correction
for blood volume is not included. This may explain the
small differences in MRGlu between both methods, espe-
cially for the lung cancer study (study A). The measured
fractional difference in MRGlu between both methods
correlates with the fractional blood volume fraction or
spillover fraction in those tumours located near large blood
Table 1 Slope, standard error and correlation coefficient (R2) of MRGlu-Patlak versus MRGlu-NLR
Study Baseline (fixed intercept
to 0)
Response (fixed intercept to 0) Baseline Response
R2 Slope±SE R2 Slope±SE R2 Slope±SE Intercept±SE R2 Slope±SE Intercept±SE
A 0.96 0.87±0.02 0.97 0.87±0.02 0.96 0.92±0.05 −0.01±0.01 0.97 0.89±0.04 −0.00±0.01
B 0.97 1.01±0.02 0.96 0.93±0.02 0.97 0.99±0.06 0.00±0.01 0.96 0.92±0.06 0.00±0.01
Fig. 1 Correlation of Patlak-
derived metabolic rate of glu-
cose (MRGlu) versus nonlinear
regression (NLR) for study A (a)
and study B (b). Baseline data
are indicated using circles and
response studies using squares.
Dashed line represents line of
identity
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vessels (Fig. 2). In theory, Patlak could provide a slightly
incorrect tumour response when there are large changes in
blood volume fraction following therapy. For study A
regression slopes between MRGlu-NLR and MRGlu-Patlak
were 0.87±0.02 for both baseline and response studies. For
study B a small difference in these regression slopes was
seen, changing from 1.01±0.02 at baseline to 0.93±0.02
following therapy. Consequently, in this case responses
measured using MRGlu-Patlak would be biased by approx-
imately 8%. This, however, should be balanced against the
main advantages of Patlak analysis, its speed and its
insensitivity to noise. The latter is relevant not only for
high accuracy, but also a good test-retest variability [31] is
needed to detect metabolic responses [11, 17]. Therefore,
despite the small bias in measured response, Patlak analysis
was used for assessing the simplified methods also for
study B.
Study A: correlation and validation of methods
For study A good correlations were found between several
semi-quantitative (simplified) measures and MRGlu-Patlak.
These results are in agreement with previous reports [11,
21, 24]. However, post-treatment studies showed decreased
correlation compared with baseline scans. A similar
observation was made using SUV for response monitoring.
A few subjects showed an SUV response that was
substantially different from the MRGlu response. This was
primarily due to high values of and/or large changes in
blood glucose levels, as correlations were higher for SKM
Table 2 Slope, standard error and correlation coefficient (R2) of various semi-quantitative methods versus MRGlu-Patlak for study A
Quantification
methods
Baseline (fixed
intercept to 0)
Response (fixed
intercept to 0)
Baseline Response
R2 Slope±SE R2 Slope±SE R2 Slope±SE Intercept
±SE
R2 Slope±SE Intercept
±SE
SUVBW 0.82
(0.82)
53.39±
3.30
0.39
(0.90)
41.76±
4.43
0.83
(0.83)
58.47±6.66 −0.61±
0.69
0.41
(0.93)
34.47±
10.37
0.97±
1.25
SUVBWg 0.83
(0.87)
48.66±
2.79
0.76
(0.91)
44.24±
2.27
0.84
(0.88)
51.64±5.71 −0.36±
0.59
0.78
(0.92)
38.90±
5.21
0.71±
0.63
SUVLBM 0.62
(0.60)
41.18±
2.53
0.03
(−0.21)
34.90±
3.21
0.77
(0.79)
29.94±4.11 1.35±
0.43
0.36
(0.71)
18.78±
6.21
2.16±
0.75
SUVLBMg 0.58
(0.69)
37.83±
2.28
0.50
(0.14)
39.28±
2.16
0.80
(0.85)
25.97±3.25 1.43±
0.34
0.77
(0.79)
25.56±
3.46
1.84±
0.42
SUVBSA 0.85
(0.85)
1,243.22±
58.60
0.33
(0.71)
1,013.89±
93.02
0.86
(0.86)
1,148.64±
118.01
11.42±
12.36
0.43
(0.92)
706.02±
204.51
41.36±
24.77
SUVBSAg 0.84
(0.91)
1,140.61±
52.76
0.79
(0.79)
1,111.32±
44.21
0.86
(0.92)
1,005.42±
101.84
16.33±
10.66
0.88
(0.91)
857.47±
78.34
34.11±
9.48
SKM 0.85
(0.90)
1.15±0.05 0.78
(0.87)
1.10±0.04 0.87
(0.91)
1.01±0.09 0.01±
0.01
0.85
(0.94)
0.88±0.09 0.02±
0.01
Values in parentheses indicate correlation after removal of the two subjects with high blood glucose values (>11 mmol⋅l−1 )
Fig. 2 Relative difference be-
tween MRGlu-Patlak and MRGlu-
NLR for both baseline and re-
sponse scans against vascular
volume fractions for study A (a)
and study B (b). Dashed line
represents line of identity
Eur J Nucl Med Mol Imaging (2011) 38:832–842 837
and SUV measures with blood glucose correction. It should
be noted, however, that these effects were caused by two of
the seven subjects. Nevertheless, these findings demon-
strate the need to correct for blood glucose levels if it
cannot be guaranteed that they will be within the normal
range.
One strategy to avoid inaccurate quantification using
SUV would be to reschedule the study when high blood
glucose levels are observed. Current guidelines [9, 14, 15]
recommend postponement of a FDG PET study if the blood
glucose level is elevated (>11 mmol⋅l−1). Moreover, this
exclusion criterion still implies that subjects with a blood
glucose level of 10 mmol⋅l−1, i.e. a value that is almost
twofold higher than the average, would still be included in
a trial. Such a high value would likely result in lower SUV
values [32].
Another option, supported by the present results, is to
include a glucose correction within the SUV calculation.
However, use of blood glucose corrections is a matter of
debate. Data have been published that either favour or
discourage use of blood glucose-corrected SUV. Recently,
Boellaard et al. [14, 27] and Velasquez et al. [31] reported
results from a multi-centre trial, showing that test-retest
variability of SUV worsened due to blood glucose
correction. Interestingly, a subset of the same data,
collected at a single centre, showed improved test-retest
variability following blood glucose correction. The possible
explanation for this discrepancy is that some of the centres
Fig. 3 Relative percentage changes in SUV and SKM due to therapy
compared with corresponding changes in MRGlu-Patlak on a lesion per
lesion basis for SUVBW (triangles), SUVLBM (circles) and SUVBSA
(squares) (a) uncorrected for blood glucose and (b) corrected for
blood glucose, and (c) for SKM in study A. Grey symbols represent
data of subjects with high blood glucose in the response scan only
(<11 mmol⋅l−1). Black symbols represent subject data with high blood
glucose values in both scans (>11 mmol⋅l−1). The open symbols
represent data from subjects having a normal blood glucose level.
Dashed line represents line of identity
Table 3 Slope, standard error and correlation coefficient (R2) of various semi-quantitative methods versus MRGlu-Patlak for study B
Quantification
methods
Baseline (fixed
intercept to 0)
Response (fixed
intercept to 0)
Baseline Response
R2 Slope±SE R2 Slope±SE R2 Slope±SE Intercept±
SE
R2 Slope±SE Intercept±
SE
SUVBW 0.11 37.64±
4.00
0.88 56.20±2.73 0.43 20.95±9.13 3.46±1.75 0.88 61.95±6.76 −0.73±
0.79
SUVBWg 0.22 37.37±
3.37
0.80 52.77±3.16 0.57 21.67±7.13 3.25±1.37 0.80 53.21±8.13 −0.06±
0.94
SUVLBM 0.15 32.77±
3.07
0.94 47.23±1.31 0.54 18.34±6.44 2.99±1.24 0.94 44.59±3.26 0.34±0.38
SUVLBMg 0.26 32.49±
2.54
0.79 44.35±2.29 0.71 18.69±4.51 2.86±0.87 0.81 38.82±5.61 0.70±0.65
SUVBSA 0.02 903.36±
95.19
0.92 1,355.20±
50.47
0.43 474.73±
206.97
88.83±
39.75
0.92 1,425.75±
127.85
−8.96±
14.85
SUVBSAg 0.16 892.40±
72.59
0.87 1,268.03±
55.81
0.68 492.08±
126.61
82.97±
24.32
0.87 1,238.16±
143.35
3.79±
16.65
SKM 0.57 0.92±0.06 0.85 1.22±0.06 0.74 0.64±0.14 0.06±0.03 0.85 1.21±0.15 0.00±0.02
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used a bedside method for measuring blood glucose, i.e. a
method that provided accurate results within 5% in 46.9%
and within 10% in 78.3% of the cases, respectively [33].
Clearly, a more accurate (laboratory) method should be
considered for response monitoring studies.
Study B: correlation and validation of methods
In contrast to study A, correlations between Patlak and all
SUV methods, including those that incorporate a blood
glucose correction, were poor for study B. During therapy,
correlations between simplified methods (SUVor SKM) and
Patlak improved to values previously found in other studies. A
relatively consistent difference between fractional SUV and
MRGlu-Patlak responses was seen. All simplified methods
showed a substantially smaller fractional change than Patlak
analysis. This was observed for both early and late response
studies and for all lesions (data not shown). SKM performed
better than SUV, which was likely due to therapy-induced
changes in FDG plasma clearance. In theory, there are two
factors that affect SUV calculations: (1) the FDG from
plasma that is available for the tumour over time (input
function) and (2) the concentration of free FDG in
intravascular and tissue spaces. For example, tumours with
low FDG uptake, having a relatively high fraction of free
FDG, may show larger discrepancies between SUV and
Patlak analysis [21, 24, 34]. Results shown in Fig. 5b
indicate that for some patient studies there were substantial
differences between nAUC of the input functions during
baseline and response scans. However, the number of
patients included is small and, therefore, any explanation
for the observed differences between SUV and MRGlu
responses requires further validation. Nevertheless, nearly
all subjects showed differences between SUV and MRGlu
responses.
Limitations
Full quantitative dynamic PET studies for response moni-
toring studies are complex resulting in discomfort for the
Fig. 4 Relative percentage changes in SUV and SKM due to therapy
compared with corresponding changes in MRGlu-Patlak on a lesion per
lesion basis for SUVBW (triangles), SUVLBM (circles) and SUVBSA
(squares) (a) uncorrected for blood glucose and (b) corrected for
blood glucose, and (c) for SKM in study B. Dashed line represents
line of identity
Table 4 Slope, standard error and correlation coefficient (R2) of percentage change in various semi-quantitative methods versus those obtained
with MRGlu-Patlak for study A
Quantification methods Fractional change (fixed intercept to 0) Fractional change
R2 Slope±SE R2 Slope±SE Intercept±SE
SUVBW 0.14 (0.62) 0.21±0.11 0.15 (0.64) 0.24±0.14 −1.96±6.26
SUVBWg 0.49 (0.61) 0.71±0.10 0.60 (0.71) 0.57±0.12 10.34±4.96
SUVLBM 0.21 (0.63) 0.26±0.10 0.21 (0.65) 0.28±0.14 −0.97±5.83
SUVLBMg 0.48 (0.60) 0.79±0.11 0.60 (0.71) 0.62±0.13 11.85±5.44
SUVBSA 0.18 (0.62) 0.25±0.11 0.19 (0.64) 0.27±0.14 −1.42±5.99
SUVBSAg 0.50 (0.60) 0.76±0.10 0.61 (0.71) 0.60±0.12 11.16±5.13
SKM 0.68 (0.70) 0.72±0.08 0.71 (0.72) 0.63±0.10 6.01±4.32
Values in parentheses indicate correlation after removal of the two subjects with high blood glucose values (>11 mmol⋅l−1 )
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subjects. Consequently, only a small number of patients are
usually recruited (and/or approval is given for a small
number of subjects). Additionally, in the present study a
limited number of successfully completed studies were
available. Despite the small number of subjects, however,
both studies illustrate potential difficulties associated using
SUV for response monitoring purposes. In the case of study
B all observed fractional changes in SUV were different
(smaller) from those seen with Patlak analysis. Therefore,
the results of this study confirm that SUV responses may
differ substantially from those obtained using full kinetic
analysis [21, 24, 25].
It should be noted that most simplified methods can be
applied in a routine clinical setting (i.e. using whole-body
scanning), while full kinetic analysis requires a dynamic scan.
An alternative could be to first perform a 60-min dynamic
scan covering the primary tumour only followed with a
whole-body acquisition to study presence and tracer uptake in
distant metastases. However, in practice this strategy would
seriously affect patient comfort and throughput. Moreover,
apart from the limited coverage of the patient, a dynamic scan
is also more sensitive to patient motion which could affect the
accuracy and precision of full kinetic analysis.
Finally, in our paper image-derived input functions were
used. The quality of these input functions might be affected
by partial volume effects, i.e. spillover of signal to and from
surrounding tissues. Therefore, in the present studies three
blood samples were drawn to perform a quality check of the
image-derived input function to avoid that these are
affected by partial volume effects and/or patient motion.
Therefore, it is expected that use of image-derived input
functions in our studies did not affect the main conclusions
of this paper. Yet, it is acknowledged that image-derived
input functions should be used with care and that at least a
quality check on the appropriateness of the input function
should be performed, e.g. as described in [11, 17].
Conclusion
In this study use of simplified methods for quantification of
treatment response with FDG PET was compared with full
kinetic analysis. Fractional changes seen with SUV differ
from those seen using full quantification based on dynamic
scans and Patlak analysis due to e.g. elevated plasma
glucose values or changes in FDG plasma clearance. SUV
may thus provide different response measures than those
observed with metabolic rate of glucose. For clinical trials
this could imply that use of SUV for assessment of drug
efficacy may under- or overestimate treatment effects
compared with full kinetic analysis and thus it would be
recommended that SUV responses are initially character-
ized prior to implementation in larger clinical trials.
Quantification methods Fractional change (fixed intercept to 0) Fractional change
R2 Slope±SE R2 Slope±SE Intercept±SE
SUVBW 0.63 0.58±0.06 0.65 0.50±0.11 −4.03±4.63
SUVBWg 0.61 0.66±0.09 0.62 0.76±0.18 4.94±7.39
SUVLBM 0.56 0.53±0.07 0.57 0.48±0.13 −2.17±5.31
SUVLBMg 0.56 0.61±0.10 0.58 0.72±0.19 5.45±7.77
SUVBSA 0.59 0.55±0.07 0.61 0.49±0.12 −3.03±4.96
SUVBSAg 0.59 0.63±0.10 0.61 0.74±0.18 5.64±7.49
SKM 0.72 0.71±0.08 0.74 0.83±0.15 5.63±6.08
Table 5 Slope, standard error
and correlation coefficient (R2)
of percentage change in various
semi-quantitative methods ver-
sus those obtained with MRGlu-
Patlak for study B
Fig. 5 a Area under the curve
(AUC) of image-derived input
functions (IDIF), normalized for
injected dose, of response versus
baseline studies for study A. b
Same for study B; early re-
sponse data are indicated using
squares and late response stud-
ies using triangles. Dashed line
represents line of identity
840 Eur J Nucl Med Mol Imaging (2011) 38:832–842
Acknowledgements The authors would like to thank the Depart-
ment of Nuclear Medicine & PET Research for FDG production and
acquisition of PET studies. The work described in this paper was in
part financed by Bristol-Myers Squibb Co. Patsuree Cheebsumon was
supported by a scholarship from the National Science and Technology
Development Agency of the Royal Thai Government.
Conflicts of interest The Department of Nuclear Medicine & PET
Research of the VU University Medical Center was financially
sponsored by Bristol-Myers Squibb Co. for participating in the trial
and for providing consultancy.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Avril NE, Weber WA. Monitoring response to treatment in
patients utilizing PET. Radiol Clin North Am 2005;43:189–
204.
2. Bastiaannet E, Groen H, Jager PL, Cobben DC, van der Graaf
WT, Vaalburg W, et al. The value of FDG-PET in the detection,
grading and response to therapy of soft tissue and bone sarcomas;
a systematic review and meta-analysis. Cancer Treat Rev
2004;30:83–101.
3. Erdi YE. The use of PET for radiotherapy. Curr Med Imaging Rev
2007;3:3–16.
4. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ,
Lyman GH, et al. Recommendations on the use of 18F-FDG PET
in oncology. J Nucl Med 2008;49:480–508.
5. de Geus-Oei LF, van der Heijden HF, Corstens FH, Oyen WJ.
Predictive and prognostic value of FDG-PET in nonsmall-cell
lung cancer: a systematic review. Cancer 2007;110:1654–64.
6. Hoekstra CJ, Stroobants SG, Smit EF, Vansteenkiste J, van
Tinteren H, Postmus PE, et al. Prognostic relevance of response
evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emis-
sion tomography in patients with locally advanced non-small-cell
lung cancer. J Clin Oncol 2005;23:8362–70.
7. Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein
M, Guermazi A, et al. Use of positron emission tomography for
response assessment of lymphoma: consensus of the Imaging
Subcommittee of International Harmonization Project in Lympho-
ma. J Clin Oncol 2007;25:571–8.
8. Vansteenkiste JF, Stroobants SG. The role of positron emission
tomography with 18F-fluoro-2-deoxy-D-glucose in respiratory
oncology. Eur Respir J 2001;17:802–20.
9. Weber WA. Use of PET for monitoring cancer therapy and for
predicting outcome. J Nucl Med 2005;46:983–95.
10. Borst GR, Belderbos JS, Boellaard R, Comans EF, De Jaeger K,
Lammertsma AA, et al. Standardised FDG uptake: a prognostic
factor for inoperable non-small cell lung cancer. Eur J Cancer
2005;41:1533–41.
11. Hoekstra CJ, Hoekstra OS, Stroobants SG, Vansteenkiste J, Nuyts
J, Smit EF, et al. Methods to monitor response to chemotherapy in
non-small cell lung cancer with 18F-FDG PET. J Nucl Med
2002;43:1304–9.
12. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L,
Horning SJ, et al. Revised response criteria for malignant
lymphoma. J Clin Oncol 2007;25:579–86.
13. Juweid ME, Cheson BD. Positron-emission tomography and
assessment of cancer therapy. N Engl J Med 2006;354:496–507.
14. Boellaard R. Standards for PET image acquisition and quantitative
data analysis. J Nucl Med 2009;50 Suppl 1:11S–20S.
15. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J,
Lammertsma AA, et al. Consensus recommendations for the use
of 18F-FDG PET as an indicator of therapeutic response in
patients in National Cancer Institute Trials. J Nucl Med
2006;47:1059–66.
16. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O,
Lammertsma AA, et al. Measurement of clinical and subclinical
tumour response using [18F]-fluorodeoxyglucose and positron
emission tomography: review and 1999 EORTC recommendations.
European Organization for Research and Treatment of Cancer
(EORTC) PET Study Group. Eur J Cancer 1999;35:1773–82.
17. Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF, Postmus PE, Teule
GJ, et al. Monitoring response to therapy in cancer using [18F]-2-
fluoro-2-deoxy-D-glucose and positron emission tomography: an
overview of different analytical methods. Eur J Nucl Med
2000;27:731–43.
18. Hunter GJ, Hamberg LM, Alpert NM, Choi NC, Fischman AJ.
Simplified measurement of deoxyglucose utilization rate. J Nucl
Med 1996;37:950–5.
19. Sadato N, Tsuchida T, Nakaumra S, Waki A, Uematsu H,
Takahashi N, et al. Non-invasive estimation of the net influx
constant using the standardized uptake value for quantification of
FDG uptake of tumours. Eur J Nucl Med 1998;25:559–64.
20. Lammertsma AA, Hoekstra CJ, Giaccone G, Hoekstra OS.
How should we analyse FDG PET studies for monitoring
tumour response? Eur J Nucl Med Mol Imaging 2006;33 Suppl
1:16–21.
21. Freedman NM, Sundaram SK, Kurdziel K, Carrasquillo JA,
Whatley M, Carson JM, et al. Comparison of SUV and Patlak
slope for monitoring of cancer therapy using serial PET scans. Eur
J Nucl Med Mol Imaging 2003;30:46–53.
22. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl
Med Biol 2000;27:643–6.
23. Kim CK, Gupta NC. Dependency of standardized uptake values
of fluorine-18 fluorodeoxyglucose on body size: comparison of
body surface area correction and lean body mass correction. Nucl
Med Commun 1996;17:890–4.
24. McDermott GM, Welch A, Staff RT, Gilbert FJ, Schweiger L,
Semple SI, et al. Monitoring primary breast cancer throughout
chemotherapy using FDG-PET. Breast Cancer Res Treat
2007;102:75–84.
25. Doot RK, Dunnwald LK, Schubert EK, Muzi M, Peterson LM,
Kinahan PE, et al. Dynamic and static approaches to quantifying
18F-FDG uptake for measuring cancer response to therapy, including
the effect of granulocyte CSF. J Nucl Med 2007;48:920–5.
26. Mankoff DA, Muzi M, Krohn KA. Quantitative positron emission
tomography imaging to measure tumor response to therapy: what
is the best method? Mol Imaging Biol 2003;5:281–5.
27. Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP,
Willemsen AT, et al. The Netherlands protocol for standardisation
and quantification of FDG whole body PET studies in multi-centre
trials. Eur J Nucl Med Mol Imaging 2008;35:2320–33.
28. Brix G, Zaers J, Adam LE, Bellemann ME, Ostertag H, Trojan H,
et al. Performance evaluation of a whole-body PET scanner using
the NEMA protocol. National Electrical Manufacturers Associa-
tion. J Nucl Med 1997;38:1614–23.
29. Boellaard R, van Lingen A, Lammertsma AA. Experimental and
clinical evaluation of iterative reconstruction (OSEM) in dynamic
PET: quantitative characteristics and effects on kinetic modeling. J
Nucl Med 2001;42:808–17.
30. van der Weerdt AP, Klein LJ, Boellaard R, Visser CA, Visser FC,
Lammertsma AA. Image-derived input functions for determina-
tion of MRGlu in cardiac (18)F-FDG PET scans. J Nucl Med
2001;42:1622–9.
Eur J Nucl Med Mol Imaging (2011) 38:832–842 841
31. Velasquez LM, Boellaard R, Kollia G, Hayes W, Hoekstra OS,
Lammertsma AA, et al. Repeatability of 18F-FDG PET in a
multicenter phase I study of patients with advanced gastrointes-
tinal malignancies. J Nucl Med 2009;50:1646–54.
32. Eary JF, Mankoff DA. Tumor metabolic rates in sarcoma using
FDG PET. J Nucl Med 1998;39:250–4.
33. Dai KS, Tai DY, Ho P, Chen CC, Peng WC, Chen ST, et al.
Accuracy of the EasyTouch blood glucose self-monitoring system:
a study of 516 cases. Clin Chim Acta 2004;349:135–41.
34. Sundaram SK, Freedman NM, Carrasquillo JA, Carson JM,Whatley
M, Libutti SK, et al. Simplified kinetic analysis of tumor 18F-FDG
uptake: a dynamic approach. J Nucl Med 2004;45:1328–33.
842 Eur J Nucl Med Mol Imaging (2011) 38:832–842
